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Abstract  
Drug discovery based on development of selective ligands for a specific target intended to 
modulate its activity and revert pathophysiological process is now recognized as too simplistic 
to design effective agent for complex multifactorial diseases, characterized by diverse 
physiological dysfunctions caused by deregulations of complex networks of proteins. Major 
challenge in modern drug discovery is to rationally design multitarget drugs able to specifically 
modulate only a group of desired targets while minimizing interactions with off-targets. 
Multifactorial cerebral mechanisms implicated in mental (psychiatrics) and neurodegenerative 
diseases and interactions of the neurotransmitter systems are two main reasons for applying 
polypharmacology („multi-target”) strategy in drug discovery for these complex brain diseases. 
In this paper we review polypharmacological profile and potential therapeutic application of 
dopamine D1-like receptor antagonists. 
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Polypharmacology 
Modern drug design of multitarget ligands able to specifically modulate complex 
networks of proteins and show unique polypharmacological profiles is becoming 
increasingly important in drug discovery for complex brain diseases [1-5].   
The most significant advantages of use of multitarget drugs over the other 
therapeutic strategies is based on: improved efficacy as result of synergistic or additive 
effects caused by simultaneous and specific interactions with chosen palette of 
biological targets; better distribution in target tissue for simultaneous action on multiple 
targets; accelerated therapeutic efficacy in terms of initial onset and achievement of full 
effect; treatment of broader therapeutic range of symptoms; predictable 
pharmacokinetic profile and mitigated drug-drug interactions; lower incidence of 
molecule-based side effects; increased therapeutic interval of doses; better quality of 
treatment; improved patient compliance and tolerance; and lower incidence of 
developing target-based resistance as result of modulation of multiple targets [1, 6, 7].   
Designed Multiple Ligands (DMLs) contain the primary pharmacophore elements 
for each target which could be separated by linker (conjugate DMLs), touched at one 
point (fused) or combined by using commonalities in the structures of underlying 
pharmacophores (merged) [7, 8]. Relatively rigid and small structures of highly merged 
DMLs result in better physicochemical, pharmacokinetic and pharmacological profile 
[7, 8]. 
Based on the predicted activities on the targets and estimated pharmacokinetic 
profiles of designed multipotent ligands are selected the most promising candidates for 
further study [8-12].  
Multifactorial cerebral mechanisms and deregulation of very complex networks of 
proteins implicated in mental (schizophrenia) [13, 14] and neurodegenerative disorders 
[15], such as Parkinson's [16, 17] and Alzheimer's diseases [18]),  have generated 
intense interest in developing efficient multipotent CNS drugs [19-21]. Interactions of 
the neurotransmitter systems, such as the dopamine-glutamate interaction in 
pathogenesis of schizophrenia and Parkinson's disease [22, 23] and the serotonin-
dopamine interaction in pathogenesis of various disorders including schizophrenia, 
depression, Parkinson’s disease and drug abuse [24, 25, 26], are very important factors 
in design of multitargeted ligands with optimized pharmacological effects.  
Therefore, a more efficient polypharmacology strategy for treatment of complex 
mental/neurodegenerative diseases is based on specific interactions on set of targets 
with minimal side effects arising from interaction with defined antitargets [1, 27].  
As a result of multitarget approach [1, 7, 28, 29] many efficient CNS drugs have 
been developed. Monoamine reuptake inhibitors with serotonin 5-HT2C antagonistic 
properties were developed as novel class of antidepressants [6, 30]. Dopamine D2/D3 
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antagonists, with 5-HT2A antagonistic and 5-HT1A partial agonistic activities were 
proposed as drug candidates for therapy of schizophrenia [19, 31, 32]. 
While many neurotransmitter systems contribute to the complex pathology of 
schizophrenia, dopamine dysfunction is considered as the basis of this disorder. The 
dopamine hypothesis of schizophrenia is supported by the characteristics of the drugs 
used to treat this disorder: all antipsychotics used clinically have high affinity for 
dopamine receptors [33]. 
Parkinson disease (PD), a neurodegenerative disorder of unknown etiology, is 
characterized by extensive degeneration of dopaminergic neurons within the substantia 
nigra, resulting in tremor, rigidity, and bradykinesia. One treatment strategy is the use of 
Dopamine receptor agonists, which act directly on the depleted nigrostriatal 
dopaminergic system and have fewer undesirable side effects than L-DOPA. Dopamine 
receptor agonists can be used in conjunction with lower doses of L-DOPA in a 
combined therapy approach [33]. 
Pathophysiology of Alzheimer's disease (AD) includes progressive loss of 
cholinergic neurons, extracellular deposition of amyloid β peptide (Aβ)-containing 
plaques, metal dyshomeostasis, neuroinflammation, oxidative stress and increased 
monoamine oxidase (MAO) enzyme activity. Therefore, multipotent brain permeable 
drugs affecting few brain targets involved in the disease pathology, such as MAO and 
ChE enzymes, Aβ generation/aggregation and iron accumulations were extensively 
studied as essential therapeutic approach in treatment of AD [28, 34-43 ].” 
Quantitative Structure Activity Relationship (QSAR) modeling and related 
cheminformatic methods are developed and applied in helping to guide computer-aided-
drug-design (CADD) [44, 45] and in polypharmacology for design of ligands with 
unique polypharmacological profiles [8, 46]. Design of compounds with unique 
polypharmacology and optimal ADMET (Absorption, Distribution, Metabolism, 
Excretion, Toxicity) profile involve several steps such as: formation of chemical 
analogues of a lead, predicting their binding profiles using a group of ligand-based 
QSAR models, and synthesizing the most promising candidates with the preferred 
multitarget activities [8-10].  
For example, the MAO A/B and AChE/BuChE inhibiting activities of multitarget 
donepezil and tacrine hybrids [35, 38, 39, 40, 42, 43, 47] were used in our recent 3D-
QSAR and ASS234 optimisation studies [36, 37].  
Dopamine D1-like receptor antagonists 
Five distinct GPCRs (D1-D5 receptors) have been cloned and determined to 
mediate the actions of dopamine. The DA receptors are distinct from one another in 
pharmacology, amino acid sequence, distribution, and physiological function. Based on 
290 
 
 
their effector-coupling profiles dopamine receptors are organized into two families, the 
D1-like (D1, D5) and D2-like (D2, D3, D4) receptors [33]. 
Dopamine D1 receptor is predominantly found in the direct pathway of the striato-
nigral neurons [48, 49]. The main physiological function of the D1 receptor is to 
mediate CNS actions of dopamine to control cognitive function [50] and movement [51, 
52].  
The physiological processes under dopaminergic control include reward, emotion, 
cognition, memory, and motor activity. Dysregulation of the dopaminergic system is 
critical in a number of disease states, including Parkinson disease, Tourette’s syndrome, 
bipolar depression, schizophrenia, attention deficit hyperactivity disorder, and 
addiction/substance abuse [33]. Dopamine receptor antagonists are a mainstay in the 
pharmacotherapy of schizophrenia. 
Mice lacking the D1 receptor display deficits in multiple forms of memory, such 
as impaired spatial memory and deficits in prefrontal cortex-dependent working 
memory. Therefore the pharmacological evidence that cortical working memory can be 
modulated with D1 agonists and antagonists is in agreement with the previous findings 
[33]. 
Since D1 and D5 receptors possess about 80% homology in their transmembrane 
domains these two receptors are grouped as D1-like receptors. Pathophysiology of 
schizophrenia and related diseases is mainly based on dysfunctions in dopamine, 
serotonin, and glutamate, [33, 53, 54].  However, selective D1 antagonism alone is not 
accepted as effective antipsychotic principle [55, 56]. Therapeutic effects of typical and 
atypical neuroleptics are mostly mediated by inhibition of dopamine D2-like receptors 
(D2 and D4 receptors) and other related aminergic receptors [33]. Blockade of dopamine 
D2 and serotonin 5-HT2A receptors is mainly responsible for antipsychotic effect [57], 
while interaction with various dopamine (D1, D3, D4), serotonin (5-HT1A, 5-HT1D, 5-
HT2A, 5-HT2C), and histamine H3 receptors may produce additional antipsychotic or 
procognitive effects [54, 58, 59]. Moderate antagonistic activity at D1-receptors of 
atypical antipsychotic clozapine is suggested to be responsible for its effectiveness 
against treatment-resistant schizophrenia [55].  
Discovery of 1-phenyl-benzapine 1 (SCH 23390) [60], as D1 specific dopamine 
antagonist, has initiated development of novel benzazepines for selective targeting D1 
receptor. The pharmacological characterization of 1 (SCH 23390) [60], which has 
become the prototype of D1 antagonist, was followed by development of its 
conformationally restricted analogue 2 (SCH 39166) [61] and fused analogues and their 
derivatives (Figure 1) [62].  
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Figure 1. Structural formulas of dopamine D1-receptor antagonists. 
 
 
The R isomer of 1  (SCH 23390) [60], R(+)-7-Chloro-8-hydroxy-3-methyl-1-
phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine, is a highly potent enantioselective 
dopamine D1-like receptor antagonist with Ki of 0.2 and 0.3nM for the D1 and D5 
receptors, respectively [63, 64]. The C1-position is a chiral center and activity originates 
from the R enantiomer. Besides its high D1-like antagonistic activity, some in vitro 
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studies demonstrated moderately high binding affinity of 1  (SCH 23390) to the 5-
HT2A, 5-HT2C, 5-HT1 serotonin receptors [65-67], α2A adrenergic receptor (AR) and the 
5-HT transporter  [68]. 
Conformationally restricted derivative 2 (SCH 39166) [61] has exerted high D1 
and D5 antagonistic activity, moderately high binding affinity of 1 (SCH 23390) to the 
5-HT2 and 5-HT1 serotonin receptor subtypes [65, 66] and also to the α2a adrenergic 
receptor and the 5-HT transporter [68]. 
As a selective antagonist, 1 (SCH 23390) has been extensively used for the 
clarification and better understanding of the role of the D1 receptors in various CNS 
disorders. 
Examination of the pharmacologic profile of 1 (SCH 23390) covered its effects 
on motor behavior and memory, as well as in vivo anticonvulsant studies. The 
anticonvulsant properties of 1 (SCH 23390) indicated on the importance of D1 
dopaminergic receptor in initiation of generalized seizures. The available 
pharmacokinetic data of this compound suggest that after oral administration it 
undergoes extensive first-pass metabolism and has short half-life of around 25 minutes 
following administration of 0.3 mg/kg i.p. in the rat and therefore could not be further 
developed as a drug [63, 64]. Even the longer acting analogue 2 (SCH 39166) [61] 
showed very low oral bioavailability (0.6%). Pharmacokinetic studies has discovered 
that extensive O-glucuronidation of the phenol and N-dealkylation of the N-Me group 
of the 1 (SCH 23390) and 2 (SCH 39166) may contribute to the poor pharmacokinetic 
(PK) profile [69-71].  
Since the discovery of the 1 (SCH 23390), many dopamine D1 receptor ligands 
possessing phenyltetrahydrobenzazepines scaffold have been synthesized and analyzed. 
In particular, D1 antagonistic activity of this chemical group of compounds is 
determined by the nature of C-7 substituent, such as chlorine in the 1 (SCH 23390) or 
bromine in the SKF R-83566 [72, 73].  
The two series of 1,3-benzodiazepine based D1 antagonists, the cyclic N-aryl 
amidine and the cyclic N-aryl guanidine, was designed following a pharmacophore 
models derived from catecholamine analog 1 (SCH 23390). By replacing benzazepine 
core with 1,3-benzodiazepine, metabolically labile N3-methyl group presented in 1 
(SCH 23390) was eliminated while basicity of new model systems, with pKa values of  
8-9 and 10-11 for N-aryl amidine and N-aryl guanidine respectively, stayed within same 
range as those for the tert-azepine nitrogen center in 1 (SCH 23390). Among N1-
arylbenzodiazepines the highest affinity for D1 receptor was observed with 3-thienyl 
substituent 3 [74], Ki = 87 nM) while within cyclic N-aryl guanidines stronger basicity 
did not result in improved D1 receptor binding affinity 4 (Figure 1) [75], Ki = 129 nM)   
[74]. 
293 
 
 
A highly potent D1/D5 antagonists 5 [75]) possessing subnanomolar D1 affinity  
and high selectivity over D2 receptor were synthesized by introducing a series of  bulky 
substituents at the para position of the pendant phenyl ring in 1 (SCH 23390). The 
obtained results indicate that the para position has a high steric tolerance for 
substitution [75]. 
 Despite of their cyclic structure the benzazepines possess a considerable degree 
of conformational mobility and it is considered that equatorial orientation of the phenyl 
ring is optimal for interaction with the D1 receptor [61]. 
The preparation of conformationally restricted analogues of the 1 (SCH 23390) 
resulted in new series of  6,6a,7,8,9,13b- hexahydro-5H-benzo [d] naphtho [2,l- b] 
azepines having the B and C rings junction in two possible configurations, B/C-cis and 
B/C-trans.  Binding studies of the B/C-cis and B/C-trans series of compounds clearly 
demonstrated that conformationally rigid trans series, where the D ring is unequivocally 
fixed in an equatorial orientation, possess significantly higher D1 receptor affinity and 
selectivity over the D2 receptor. From this investigation were derived highly selective 
D1 receptor antagonist which (-)-6aS,13b R isomer (2 (SCH 39166) ) has the highest D1 
affinity  (Ki = 1.9 nM for D1 and 514 nM for D2). This finding is consistent with the fact 
that the D1 receptor activity in the 1-phenyl-1H-3-benzazepine series is associated with 
the R-enantiomers [61]. 2 (SCH 39166), also known as ecopipam, has been in clinical 
trials for several diseases including obesity [76], cocaine addiction [77] schizophrenia 
[78]. Although 2 (SCH 39166) possess high D1-like selectivity with reduced affinity for 
serotonin receptors and longer duration of action in primates in comparison to 1 (SCH 
23390), both compounds displayed low oral bioavailability [79]. 
Various 1 (SCH 23390) and 2 (SCH 39166) analogues were synthesized and 
evaluated as selective dopamine D1/D5 receptor antagonists. Some of these trials include 
investigation of the phenol bioisosteric analogues of 1 (SCH 23390) and 2 (SCH 
39166), such as benzotriazole, indole, benzimidazole, benzimidazolone and 
benzothiazolone. The designed corresponding heterocyclic systems, containing an N-H 
hydrogen bond donor group, retained the characteristic of the phenol group that are 
thought to be responsible for interaction with the receptor. Benzotriazole analogue of 2 
(SCH 39166), 6 (Figure 1) [68]), displayed very low affinity for D1 receptor (Ki = 583 
nM) suggested that conformer A was not the active binding conformer. In comparison 
with 6 [68], indole analogue of 2 (SCH 39166) 7 [68] displayed appreciable affinity for 
D1 receptor. Further optimization of the hydrogen bond donating properties of different 
heterocyclus analogues of conformer B also indicated the preference of conformation B 
over A, whereby hydrogen-bond donating directionality has been established. Among 
the designed compounds highly selective D1/D5 antagonists, benzimidazolone analogue 
(8 [68], Ki = 7 nM for D1 and 4.2 nM for D5) and its corresponding NH benzazepine (9 
[68], Ki = 16.5 nM for D1 and 2.4 nM for D5) together with benzothiazolone analogue 
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(10 [68], Ki = 2.1 nM for D1, 2.8 nM for D5) and its corresponding NH benzazepine (11 
[68], Ki = 6.5 for D1 and 1.7 for D5) were of particular interest in terms of their overall 
profiles (Figure 1). Improved pharmacokinetic profiles of heterocyclic isosteres 
demonstrated by rats plasma levels is associated with higher metabolic stability with 
respect to O-glucuronidation. In contrast, biological evaluation of phenol bioisosteric 
analogues of 1 (SCH 23390) revealed huge decrease in the D1 binding affinity with 
exception of 12 [68] which was identified as a potent D1/D5 ligand in this series but 
without significant improvement in pharmacokinetic profile compared to 1 (SCH 
23390). This finding indicated that molecular rigidity might play important role in 
improving the pharmacokinetic properties [68]. 
Functionalization of the D-ring of 2 (SCH 39166) with the special focus on the C-
3 and C-4 positions have been also examined [75, 80].  Several 2 (SCH 39166) analogs 
substituted on the C-3 and C-4 positions with amino, amido and sulfonamido groups (-
NH2, -NHCOC3H5, -NHSO2CH3, -NHSO2CH2CH3, -NHCONHCH2CH3, -NHCONH-
2.6-Cl2C6H3, -NHCO2CH2CH3), showed strong D1 antagonistic activity [75, 80]. 
Results of the study indicated on far more significant substitution on C-3 (13 [75] than 
on C-4 (14 [75]) position of 2 (SCH 39166) ligands for strong and selective D1 receptor 
antagonism. In addition, high selectivity over D2 receptor was achieved with C-3 
derivatisation while moderate selectivity over D2 was observed in C-4 series. The most 
representative compound, sulfonamido D1 antagonist (13 [75]) showed even higher 
affinity to D1 receptor (Ki = 0.5 nM) and selectivity over D2, D4, 5HT2a and α2a 
receptors compare to parent drug 2 (SCH 39166) while D5 affinity was somewhat 
lower. This compound also posses improved pharmacokinetic profile and bioavailability 
compared to 2 (SCH 39166) (rat AUC: 2486 ng/mL.hr and 156 ng/mL.hr for 13 [75] 
and 2 (SCH 39166) respectively; rat bioavailability: 29% and 0.6% for 13 [70] and 2 
(SCH 39166) respectively [75]). On the other side the position 4 of D-ring can tolerate 
a wide variety of functional groups such as –CHO, -CH2OH, -CN, -CO2Me, -OH and 
pyrrolidine-2-one wherein in addition to high D1 antagonistic activity, selectivity over 
D2 receptor is also retained (15 [80]) (Figure 1). However, the most potent dopamine D1 
antagonists from C-4 series were obtained by the introduction of an aromatic group at 
the position 4 of the D-ring of 2 (SCH 39166). Almost every aromatic group including 
phenyl (16 [80] D1 Ki = 0.2 nM), 2-thienyl (17 [80] D1 Ki = 0.9 nM), piridinyl (18 [80] 
D1 Ki = 0.3 nM) and indolyl (19 [80] D1 Ki = 0.6 nM) are well tolerated at the 4-
position. Regarding the D2 selectivity it was observed that unsubstituted phenyl 
derivative 16 [80], as well as 1H-Indol-5-yl (19 [80]) and 2-thienyl (17 [80]) derivatives 
possess significant affinities for D2 receptor (Figure 1). Among tested compounds 
improved pharmacokinetic profile compared to 2 (SCH 39166) (AUC = 156 h µg/mL, 
Cmax = 72 ng/mL, Tmax = 0.5 h) showed 2-thienyl derivative, 17 [81] (AUC = 353 h 
µg/mL, Cmax = 90 ng/mL, Tmax = 2 h). Oxime analogs are also well tolerated in the 
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position 4 (20 [80] and 21 [80]). The most potent compound in this series is the O-
benzyl oxime 21 [80] with D1 Ki of 0.2 nM and notably higher D2 Ki of 69 nM   [80].  
Besides this series of benzodiazepines, derivatives of alkaloids such as boldine, 
predicentrine and l-(S)-stepholidine have been synthesized and examined as potential 
D1-ligands [81,83]. 
The neuroleptic-like behavior of aporphine alkaloid 22 (boldine) suggested that it 
may act as dopamine receptors antagonist. In vitro binding studies showed micromolar 
nonselective D1- and D2-activity of 22 (boldine) while in vivo central antidopaminergic 
activity was negligible (Figure 1) [81, 82]. Unlike apomorphine which typical agonist 
activity is associated with R configuration at C-6a position, 22 (boldine) and its 9-O-
methylated analogue of 23 (predicentrine) share the S configuration and shows 
antagonistic properties. The lack of 22 (boldine) activity in vivo could be related to its 
unfavorable pharmacokinetics such as short plasma half-life of only few minutes 
(Figure 1) [83]. Contrary, halogenated derivatives of 22 (boldine) and 23 
(predicentrine) showing higher lipophilicity displayed increased affinity for the D1-like 
receptors and higher selectivity over the D2-like receptors. The highest affinity for D1 
receptor and selectivity over D2 receptor among brominated, chlorinated and iodinated 
22 (boldine) derivatives showed 3-iodo-boldine (D1, Ki = 2 nM, Ki ratio D2/D1 = 34) 
[82, 83]. Similar behavior was noticed among halogenated 23 (predicentrine) 
derivatives where 3-iodo-predicentrine [82] (D1, Ki = 6 nM) displayed the highest 
affinity as well as selectivity over D2-like receptors, being 140-fold more selective for 
D1-like receptors. Unlike 3-bromo-boldine derivative, 24 (3-bromo-predicentrine) 
[82] possesses higher affinity and selectivity but lower than 3-iodo-predicentrine 
(Figure 1)   [82]. 
Removing of hydroxy group and introducing methoxy group in benzene moiety of 
25 (l-(S)-stepholidine) resulted in greater affinity and reversed function (from agonistic 
to antagonistic) at D1 receptor (26 [84]). These results were in accordance with 
molecular docking studies at human D1 receptor [84. The compound 26 [84] displayed 
2.5-fold higher affinity for the D1 receptor (Ki = 2.53 nM) compared to 25 (l-(S)-
stepholidine) (D1, Ki = 6.23 nM) and binding affinities for D2, 5-HT1A, and 5-HT2A 
receptors (Figure 1)   [84].  
 
Conclusion 
Based on the results of the studies novel selective D1/D5 antagonists, 8, 9 10, 11, 
and 12 [68], were of particular interest in terms of their overall binding profiles for 
dopamine D1/D5 receptors and α2A-AR, improved pharmacokinetic properties compared 
to their leads 1 (SCH 23390) and 2 (SCH 39166), and moderate binding affinity to the 
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5-HT transporter (Ki = 540 nM, 6220 nM, 842 nM, 2950 nM, and 137 nM, respectively 
[68]. The indazole compound 12 in this series was identified as a potent D1/D5 ligand 
[68]. Lead compound 2 has been in human clinical trials for a variety of diseases, 
including schizophrenia, cocaine addiction, and obesity [68]. 
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Kratak sadržaj 
Istraživanje novih lekova koji deluju kao selektivni ligandi za određeno ciljno mesto i 
tako usporavaju ili zaustavljaju patofiziološki process danas se smatra nedovoljno efikasnim u 
razvoju lekova za kompleksna oboljenja nastala usled više patofizioloških procesa i promena u 
nekoliko signalnih puteva. Najveći izazov predstavlja razvoj lekova koji specifično modifikuju 
aktivnost nekoliko izabranih ciljnih mesta dejstva, a istovremeno minimalno stupaju u 
interakciju sa ostalim biomolekulima. Kompleksni patofiziološki procesi psihijatrijskih i 
neurodegenerativnih oboljenja i interakcija neurotransmiterskih sistema su dva ključna razloga 
za primenu strategije polifarmakologije (strategije multiplih ciljnih mesta) u razvoju efikasnih 
lekova koji deluju na centralni nervni sistem. U ovom radu dat je pregled polifarmakoloških 
profila i potencijalne terapijske primene antagonista receptora koji pripadaju D1 familiji 
dopaminskih receptora.  
 
Ključne reči: polifarmakologija, multitarget lekovi, dopaminski receptori 
 
 
